Kenvue Inc. (NYSE:KVUE) Shares Bought by Pathway Financial Advisers LLC

Pathway Financial Advisers LLC lifted its holdings in Kenvue Inc. (NYSE:KVUE) by 19.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 12,697 shares of the company’s stock after purchasing an additional 2,040 shares during the quarter. Pathway Financial Advisers LLC’s holdings in Kenvue were worth $271,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. AMF Tjanstepension AB grew its position in Kenvue by 187.3% in the 3rd quarter. AMF Tjanstepension AB now owns 120,477 shares of the company’s stock valued at $2,787,000 after buying an additional 78,540 shares in the last quarter. Exchange Traded Concepts LLC lifted its stake in shares of Kenvue by 371.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 29,887 shares of the company’s stock worth $691,000 after acquiring an additional 23,551 shares during the period. Vontobel Holding Ltd. boosted its holdings in shares of Kenvue by 13.4% in the third quarter. Vontobel Holding Ltd. now owns 22,594 shares of the company’s stock valued at $523,000 after acquiring an additional 2,677 shares in the last quarter. LaFleur & Godfrey LLC increased its stake in shares of Kenvue by 12.5% during the third quarter. LaFleur & Godfrey LLC now owns 62,650 shares of the company’s stock valued at $1,449,000 after acquiring an additional 6,985 shares during the period. Finally, Wolff Wiese Magana LLC raised its holdings in Kenvue by 0.7% during the third quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company’s stock worth $1,781,000 after purchasing an additional 501 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. Citigroup lowered their price target on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 15th. UBS Group lowered their target price on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a report on Friday, February 7th. Royal Bank of Canada reissued a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Deutsche Bank Aktiengesellschaft cut shares of Kenvue from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Piper Sandler raised shares of Kenvue from a “neutral” rating to an “overweight” rating and increased their target price for the company from $21.00 to $26.00 in a research note on Monday, January 6th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, Kenvue presently has an average rating of “Hold” and an average price target of $23.00.

Kenvue Trading Up 0.2 %

NYSE KVUE opened at $20.96 on Thursday. The firm’s 50 day moving average price is $21.41 and its two-hundred day moving average price is $22.03. The stock has a market cap of $40.19 billion, a price-to-earnings ratio of 39.55, a PEG ratio of 2.16 and a beta of 1.45. Kenvue Inc. has a twelve month low of $17.67 and a twelve month high of $24.46. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. Equities analysts anticipate that Kenvue Inc. will post 1.05 EPS for the current year.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.91%. The ex-dividend date of this dividend is Wednesday, February 12th. Kenvue’s dividend payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.